NeuroPace Shares Plunge 33.61% After-Hours: Here's What Investors Should Know - NeuroPace
NeuroPace, a medical technology firm specializing in epilepsy care, saw its stock price fall by 33.61% in after-hours trading following the release of its third-quarter financial results. The significant drop occurred as the company failed to meet the expectations that Wall Street analysts had set for its top-line performance during the period ending September 30.
Revenue Miss Triggers Stock Selloff
The California-based developer reported total revenue of $23.1 million for the third quarter. This figure represents a 1.1% decline compared to the $23.4 million the company generated during the same three-month window in the previous year. Furthermore, the results fell short of the $27.14 million that
Source: benzinga.com · 2026-11-13